RayKnowChina Research Map
Shortlist

Not yet recruitingLung cancerN/A

Registered title, quoted from ClinicalTrials.gov

Pulsed Field Ablation for the Treatment of Malignant Lung Tumors

An open trial on lung cancer, registered on ClinicalTrials.gov. Led by Shanghai Chest Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 18 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead sponsorShanghai Chest Hospital上海市胸科医院ShanghaiHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07889297, read on 18 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 6

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (6 points)Hide the checklist
  1. 18 years to Not stated; sex: all

    Registered eligibility fields

  2. Pathologically confirmed primary peripheral non-small cell lung cancer with a clinical stage of T1N0M0, stage IA, including newly developed tumors after surgery and multiple primary lung cancers; or pulmonary metastatic tumors for which the primary lesion has been completely resected and the maximum tumor diameter is 3 cm or less.

    Inclusion criterion 2

  3. The target lesion has received radiotherapy within the previous 6 months.

    Exclusion criterion 8

  4. Eastern Cooperative Oncology Group (ECOG) performance status greater than 2.

    Exclusion criterion 7

  5. Platelet count less than 70 x 10\^9/L, or anticoagulant and/or antiplatelet medication that has not been discontinued for at least 1 week before ablation, except for prophylactic preoperative use of low-molecular-weight heparin.

    Exclusion criterion 2

  6. Pregnancy or breastfeeding, or a female or male participant planning pregnancy or conception during the study.

    Exclusion criterion 13

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: stage or severity, as the trial defines it; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07889297, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion Criteria:

  • Age 18 years or older.
  • Pathologically confirmed primary peripheral non-small cell lung cancer with a clinical stage of T1N0M0, stage IA, including newly developed tumors after surgery and multiple primary lung cancers; or pulmonary metastatic tumors for which the primary lesion has been completely resected and the maximum tumor diameter is 3 cm or less.
  • No more than three lung tumors.
  • The participant refuses surgery or is considered unsuitable for surgery.
  • The participant refuses or is considered unsuitable for radiotherapy, has not responded to previous radiotherapy, or has experienced disease progression after radiotherapy.
  • In the investigator's judgment, the target lesion can be reached through the bronchial route and pulsed field ablation is technically feasible.
  • The participant voluntarily agrees to participate, provides written informed consent, and is able and willing to comply with all study procedures.

Exclusion Criteria:

  • Severe bleeding tendency or an uncorrectable coagulation disorder, including a prothrombin time greater than 18 seconds or prothrombin activity less than 40%.
  • Platelet count less than 70 x 10\^9/L, or anticoagulant and/or antiplatelet medication that has not been discontinued for at least 1 week before ablation, except for prophylactic preoperative use of low-molecular-weight heparin.
  • Imaging performed within 1 month before the procedure showing lymph node metastasis or extrapulmonary metastasis, except for extrapulmonary metastases that have been controlled by local treatment.
  • Extensive pulmonary metastases with an estimated survival of less than 3 months.
  • A condition considered to confer a high risk for the ablation procedure, including severe comorbidities, active infection, severe pulmonary arterial hypertension, severe heart disease, severe hypertension, or severe respiratory failure.
  • A history of arrhythmia within the previous 2 years, including atrial tachyarrhythmia or any ventricular tachyarrhythmia; a history of second-degree Mobitz type II or third-degree atrioventricular block; or sinus bradycardia with a heart rate below 45 beats per minute.
  • Eastern Cooperative Oncology Group (ECOG) performance status greater than 2.
  • The target lesion has received radiotherapy within the previous 6 months.
  • The shortest distance between the target lesion and the trachea, main bronchus, esophagus, branches of the aortic arch, main pulmonary artery, right or left pulmonary artery trunk, or heart is less than 1 cm; or the distance between the pleural margin of the tumor and the pleura is less than 1 cm.
  • A cardiac pacemaker, implantable cardioverter-defibrillator, or another electronic device or metal component is present within or near the planned ablation area.
  • Contraindication to bronchoscopy.
  • Contraindication to general anesthesia.
  • Pregnancy or breastfeeding, or a female or male participant planning pregnancy or conception during the study.
  • Current participation in another clinical study involving an investigational product.
  • Any other condition that, in the investigator's judgment, makes the individual unsuitable for participation in this study.

Quoted from ClinicalTrials.gov, NCT07889297, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07889297, read on 18 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07889297